erlotinib hydrochloride has been researched along with incb-018424 in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (incb-018424) | Trials (incb-018424) | Recent Studies (post-2010) (incb-018424) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 1,487 | 185 | 1,451 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | incb-018424 (IC50) |
|---|---|---|---|
| Cyclin-G-associated kinase | Homo sapiens (human) | 0.12 | |
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 0.0573 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.0001 | |
| Tyrosine-protein kinase JAK1 | Homo sapiens (human) | 0.0327 | |
| Non-receptor tyrosine-protein kinase TYK2 | Homo sapiens (human) | 0.0962 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 0.3547 | |
| AP2-associated protein kinase 1 | Homo sapiens (human) | 0.1 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.015 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Y; Du, P; Kim, HJ; Lee, HJ; Settleman, J; Zhuang, G | 1 |
| Bromberg, J; Chang, Q; Gao, SP; Kris, MG; Perez, L; Riely, GJ; Yu, HA | 1 |
1 trial(s) available for erlotinib hydrochloride and incb-018424
| Article | Year |
|---|---|
A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Prognosis; Prospective Studies; Pyrazoles; Pyrimidines; Survival Rate | 2017 |
1 other study(ies) available for erlotinib hydrochloride and incb-018424
| Article | Year |
|---|---|
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Interleukin-6; Janus Kinase 1; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mice, SCID; Mutation; Nitriles; Oncogenes; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridazines; Pyrimidines; Quinazolines; ras Proteins; Receptors, Fibroblast Growth Factor; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2014 |